Burtness, B., Harrington, K. J., Greil, R., Souli<U+00E8>res, D., Tahara, M., de Castro Jr, G., ... & Abel, E. (2019). Pembrolizumab alone or with chemotherapy
versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label,
phase 3 study. The Lancet, 394(10212), 1915-1928.